Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
8.70
+0.55 (6.75%)
Mar 4, 2026, 10:45 AM EST - Market open
Immix Biopharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Immix Biopharma stock have an average target of 13, with a low estimate of 12 and a high estimate of 14. The average target predicts an increase of 49.43% from the current stock price of 8.70.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immix Biopharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Initiates $14 | Buy | Initiates | $14 | +60.92% | Feb 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +37.93% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | -8.05% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | -19.54% | Jun 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | -19.54% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.68
from -0.76
EPS Next Year
-0.50
from -0.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.55 | -0.30 | |||
| Avg | -0.68 | -0.50 | |||
| Low | -0.75 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.